Empirical therapies among adults hospitalized for community-acquired upper urinary tract infections: A decision-tree analysis of mortality, costs, and resistance

American Journal of Infection Control

Volumn 43, Issue 9, 2015, Pages e53-e59

  Parienti, Jean Jacques ^a,b   Lucet, J C ^a,c   Lefort, A ^d   Armand Lefevre L ^a,c   Wolff, M ^c   Caron, F ^e   Cattoir, V ^b   Yazdanpanah, Y ^a,c  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b CHU CÔTE DE NACRE   (France)

^c BICHAT HOSPITAL   (France)

^d BEAUJON HOSPITAL   (France)

^e HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Carbapenem; Cost effectiveness; Empirical therapy; Urinary tract infection

Indexed keywords

CARBAPENEM; CEFTRIAXONE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED UPPER URINARY TRACT INFECTION; COST EFFECTIVENESS ANALYSIS; DECISION TREE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MORTALITY; PREVALENCE; RISK FACTOR; SINGLE DRUG DOSE; URINARY TRACT INFECTION; COHORT ANALYSIS; COST; DECISION SUPPORT SYSTEM; ECONOMICS; EMPIRICAL RESEARCH; HOSPITAL MORTALITY; HOSPITALIZATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG RESISTANCE, BACTERIAL; EMPIRICAL RESEARCH; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84941601283     PISSN: 01966553     EISSN: 15273296     Source Type: Journal    
DOI: 10.1016/j.ajic.2015.05.033     Document Type: Article

References (42)

1. D.L. Paterson, W.C. Ko, A. Von Gottberg, J.M. Casellas, L. Mulazimoglu, K.P. Klugman, and et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory J Clin Microbiol 39 2001 2206 2212
2. M.J. Schwaber, and Y. Carmeli Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis J Antimicrob Chemother 60 2007 913 920
3. W.C. Rottier, H.S. Ammerlaan, and M.J. Bonten Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis J Antimicrob Chemother 67 2012 1311 1320
4. K.K. Kumarasamy, M.A. Toleman, T.R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, and et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study Lancet Infect Dis 10 2010 597 602
5. B. Foxman, K.L. Klemstine, and P.D. Brown Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality Ann Epidemiol 13 2003 144 150
6. G.S. Martin, D.M. Mannino, S. Eaton, and M. Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554
7. J.R. Zahar, J.F. Timsit, M. Garrouste-Orgeas, A. Français, A. Vesin, A. Descorps-Declere, and et al. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality Crit Care Med 39 2011 1886 1895
8. C. van Nieuwkoop, J.W. van't Wout, I.C. Spelt, M. Becker, E.J. Kuijper, J.W. Blom, and et al. Prospective cohort study of acute pyelonephritis in adults: safety of triage towards home based oral antimicrobial treatment J Infect 60 2010 114 121
9. K. Gupta, T.M. Hooton, K.G. Naber, B. Wullt, R. Colgan, L.G. Miller, and et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases Clin Infect Dis 52 2011 e103 e120
10. M. Tumbarello, E.M. Trecarichi, M. Bassetti, F.G. De Rosa, T. Spanu, E. Di Meco, and et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system Antimicrobial Agents Chemother 55 2011 3485 3490
11. A. Lefort, X. Panhard, O. Clermont, P.L. Woerther, C. Branger, F. Mentré, and et al. Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia J Clin Microbiol 49 2011 777 783
12. L. Vidal, A. Gafter-Gvili, S. Borok, A. Fraser, L. Leibovici, and M. Paul Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials J Antimicrob Chemother 60 2007 247 257
13. A. Søraas, A. Sundsfjord, I. Sandven, C. Brunborg, and P.A. Jenum Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae - a case-control study in a low prevalence country PloS One 8 2013 e69581
14. D.J. Hoban, C. Lascols, L.E. Nicolle, R. Badal, S. Bouchillon, M. Hackel, and et al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010 Diagn Microbiol Infect Dis 74 2012 62 67
15. S. Aguilar-Duran, J.P. Horcajada, L. Sorlí, M. Montero, M. Salvadó, S. Grau, and et al. Community-onset healthcare-related urinary tract infections: comparison with community and hospital-acquired urinary tract infections J Infect 64 2012 478 483
16. S.K. Bouchillon, R.E. Badal, D.J. Hoban, and S.P. Hawser Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011 Clin Ther 35 2013 872 877
17. Y. Doi, Y.S. Park, J.I. Rivera, J.M. Adams-Haduch, A. Hingwe, E.M. Sordillo, and et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States Clin Infect Dis 56 2013 641 648
18. A. Gündoʇdu, Y.B. Long, and M. Katouli Prevalence and pathogenesis of extended-spectrum beta-lactamase producing Escherichia coli causing urinary tract infection in hospitalized patients Eur J Clin Microbiol Infect Dis 31 2012 3107 3116
19. S. Meier, R. Weber, R. Zbinden, C. Ruef, and B. Hasse Extended-spectrum β-lactamase-producing gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy Infection 39 2011 333 340
20. M.D. Zilberberg, and A.F. Shorr Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009 Infect Control Hosp Epidemiol 34 2013 940 946
21. A. Artero, J. Alberola, J.M. Eiros, J.M. Nogueira, and A. Cano Pyelonephritis in pregnancy. How adequate is empirical treatment? Rev Esp Quimioter 26 2013 30 33
22. C. Bin, W. Hui, Z. Renyuan, N. Yongzhong, X. Xiuli, X. Yingchun, and et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli Diagn Microbiol Infect Dis 56 2006 351 357
23. E.P. Hyle, A.D. Lipworth, T.E. Zaoutis, I. Nachamkin, W.B. Bilker, and E. Lautenbach Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection Arch Intern Med 165 2005 1375 1380
24. J.H. Jeon, K. Kim, W.D. Han, S.H. Song, K.U. Park, J.E. Rhee, and et al. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high Antimicrobial Agents Chemother 56 2012 3043 3046
25. S.S. Lee, Y. Kim, and D.R. Chung Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis J Infect 62 2011 159 164
26. S. Lee, D.Y. Song, S.H. Cho, and K.T. Kwon Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone Microb Drug Resist 20 2014 39 44
27. T.P. Le, and L.G. Miller Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis Clin Infect Dis 33 2001 615 621
28. G. Peralta, M. Lamelo, P. Alvarez-García, M. Velasco, A. Delgado, J.P. Horcajada, and et al. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study BMC Infect Dis 12 2012 245
29. B. Kim, J. Kim, M.R. Seo, S.H. Wie, Y.K. Cho, S.K. Lim, and et al. Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea Infection 41 2013 603 612
30. G.S. Tansarli, D.E. Karageorgopoulos, A. Kapaskelis, and M.E. Falagas Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence Expert Rev Anti Infect Ther 11 2013 321 331
31. M.J. Dautzenberg, A.N. Wekesa, M. Gniadkowski, A. Antoniadou, H. Giamarellou, G.L. Petrikkos, and et al. The association between colonization with carbapenemase-producing enterobacteriaceae and overall ICU mortality: an observational cohort study Crit Care Med 43 2015 1170 1177
32. I.H. Spicknall, B. Foxman, C.F. Marrs, and J.N. Eisenberg A modeling framework for the evolution and spread of antibiotic resistance: literature review and model categorization Am J Epidemiol 178 2013 508 520
33. E. Duchêne, E. Montassier, D. Boutoille, J. Caillon, G. Potel, and E. Batard Why is antimicrobial de-escalation under-prescribed for urinary tract infections? Infection 41 2013 211 214
34. E. Ruppé, B. Lixandru, R. Cojocaru, C. Büke, E. Paramythiotou, C. Angebault, and et al. Relative fecal abundance of extended-spectrum-β-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women Antimicrobial Agents Chemother 57 2013 4512 4517
35. G. Birgand, L. Armand-Lefevre, I. Lolom, E. Ruppe, A. Andremont, and J.C. Lucet Duration of colonization by extended-spectrum β-lactamase-producing Enterobacteriaceae after hospital discharge Am J Infect Control 41 2013 443 447
36. E.P. Hyle, M.J. Ferraro, M. Silver, H. Lee, and D.C. Hooper Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes Infect Control Hosp Epidemiol 31 2010 1242 1249
37. R. Ben-Ami, J. Rodríguez-Baño, H. Arslan, J.D. Pitout, C. Quentin, E.S. Calbo, and et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients Clin Infect Dis 49 2009 682 690
38. S.Z. Kassakian, and L.A. Mermel Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria Antimicrob Resist Infect Control 3 2014 9
39. S.K. Bouchillon, R.E. Badal, D.J. Hoban, and S.P. Hawser Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011 Clin Ther 35 2013 872 877
40. M. Paul, V. Shani, E. Muchtar, G. Kariv, E. Robenshtok, and L. Leibovici Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis Antimicrobial Agents Chemother 54 2010 4851 4863
41. A.F. Shorr, S.T. Micek, E.C. Welch, J.A. Doherty, R.M. Reichley, and M.H. Kollef Inappropriate antibiotic therapy in gram-negative sepsis increases hospital length of stay Crit Care Med 39 2011 46 51
42. L. Armand-Lefèvre, C. Angebault, F. Barbier, E. Hamelet, G. Defrance, E. Ruppé, and et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients Antimicrobial Agents Chemother 57 2013 1488 1495